Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug;46(8):815-823.
doi: 10.1111/pace.14763. Epub 2023 Jul 18.

Transvenous lead extraction of implantable cardioverter-defibrillators: A comprehensive outcome-and risk factor analysis

Da-Un Chung  1 , Heiko Burger  2 , Lukas Kaiser  1 , Brigitte Osswald  3 , Volker Bärsch  4 , Herbert Nägele  5 , Michael Knaut  6 , Hermann Reichenspurner  7   8 , Nele Gessler  1   8 , Stephan Willems  1   8 , Christian Butter  9 , Simon Pecha  7   8 , Samer Hakmi  1 ; GALLERY investigators
Affiliations

Transvenous lead extraction of implantable cardioverter-defibrillators: A comprehensive outcome-and risk factor analysis

Da-Un Chung et al. Pacing Clin Electrophysiol. 2023 Aug.

Abstract

Background: Device complications, such as infection or lead dysfunction necessitating transvenous lead extraction (TLE) are continuously rising amongst patients with transvenous implantable-cardioverter-defibrillator (ICD).

Objectives: Aim of this study was to characterize the procedural outcome and risk-factors of patients with indwelling 1- and 2-chamber ICD undergoing TLE.

Methods: We conducted a subgroup analysis of all ICD patients in the GALLERY (GermAn Laser Lead Extraction RegistrY) database. Predictors for procedural failure and all-cause mortality were assessed.

Results: We identified 842 patients with an ICD undergoing TLE with the mean age of 62.8 ± 13.8 years. A total number of 1610 leads were treated with lead dysfunction (48.5%) as leading indication for extraction, followed by device-related infection (45.4%). Lead-per-patient ratio was 1.91 ± 0.88 and 60.0% of patients had dual-coil defibrillator leads. Additional extraction tools, such as mechanical rotating dilator sheaths and snares were utilized in 6.5% of cases. Overall procedural complications occurred in 4.3% with 2.0% major complications and a procedure-related mortality of 0.8%. Clinical success rate was 97.9%. All-cause in-hospital mortality was 3.4%, with sepsis being the leading cause for mortality. Multivariate analysis revealed lead-age ≥10 years (OR:5.82, 95%CI:2.1-16.6; p = .001) as independent predictor for procedural failure. Systemic infection (OR:9.57, 95%CI:2.2-42.4; p < .001) and procedural complications (OR:8.0, 95%CI:2.8-23.3; p < .001) were identified as risk factors for all-cause mortality.

Conclusions: TLE is safe and efficacious in patients with 1- and 2-chamber ICD. Although lead dysfunction is the leading indication for extraction, systemic device-related infection is the main driver of all-cause mortality for ICD patients undergoing TLE.

Keywords: CIED-complications; Implantable cardioverter-defibrillator (ICD); Lead management; cardiac-device-related infections; lead dysfunction; transvenous lead extraction.

PubMed Disclaimer

References

REFERENCES

    1. Raatikainen MJP, Arnar DO, Merkely B, Camm AJ, Hindricks G. Access to and clinical use of cardiac implantable electronic devices and interventional electrophysiological procedures in the European Society of Cardiology Countries: 2016 Report from the European Heart Rhythm Association. Europace. 2016;18:iii1-iii79. doi:10.1093/europace/euw244
    1. Priori SG, Blomström-Lunqvist C, Mazzanti A, et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2015;36:2793-2867. doi:10.1093/eurheartj/ehv316
    1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599-3726. doi:10.1093/eurheartj/ehab368
    1. Ahmed FZ, Blomström-Lundqvist C, Bloom H, et al. Use of healthcare claims to validate the prevention of arrhythmia device infection trial cardiac implantable electronic device infection risk score. EP Europace. 2021;23:1446-1455. doi:10.1093/europace/euab028
    1. Ludwig S, Theis C, Brown B,itthohn A, Lux W, Goette A. Incidence and costs of cardiac device infections: retrospective analysis using German health claims data. J Comp Eff Res. 2018;7:483-492. doi:10.2217/cer-2017-0080

Publication types

LinkOut - more resources